Recro To Consider Dispute Resolution With FDA After Complete Response Letter

By |2020-03-30T10:13:30-04:00March 24th, 2019|Categories: Bill Langbein, Healthcare, Insights, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , , |

Shares of Recro Pharma, Inc. (NASDAQ:REPH) likely will fall in [...]